Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population
  1. Home
  2. Publications
  3. Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population

Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population

Authors:
  • MWMoritz Weber
    Moritz Weber
  • AHAlexander Freiherr von Hammerstein-Equord
    Alexander Freiherr von Hammerstein-Equord
  • SAStefan Andreas
    Stefan Andreas
  • ARAchim Rittmeyer
    Achim Rittmeyer

Open Access
Publisher website
Google Scholar
  • 6 April 2026
    • journal article
    • correction
    • Published by Springer Nature in Cancer Immunology, Immunotherapy
    • Vol. 75  (5) , 138
    • DOI:10.1007/s00262-026-04360-9
    • PMID:41942614
    • PMCID:PMC13053719
Abstract
No abstract available
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.